Inspira Technologies announces business plan targets

Inspira Technologies presented a business plan with targets for the company’s next-generation technologies on a company conference call. Inspira unveiled plans to build an opportunity for a share of the $19B mechanical ventilation market. Alongside the ongoing development of the Inspira ART Gen 2 adaptive blood oxygenation technology, the company is working on the multi-site deployment of the 510(k) FDA cleared Inspira ART100, a cardiopulmonary support device. Under the existing distribution agreements with Glo-Med Networks, the company has already received the first purchase order from the U.S. distributor, with its first shipment scheduled for Q4. Inspira is on track to submit its HYLA blood sensor, a key component of the Inspira ART Gen 2 system, for FDA Clearance with company plans to integrate the technology into the next generation of the Inspira ART100 device. In addition, Inspira is on track with phase 2 research and development for the VORTX blood delivery system and phase 3 verification and validation testing of the HYLA blood sensor.